Neurology · 2006 · 83 citations · 11 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyNeuro-oncologyBrain TumorsCentral Nervous System Tumor PharmacotherapyChemotherapy Toxicity ManagementCytotoxic ChemotherapyGlioblastomaToxicity ManagementBrain ToxicityGlioblastoma ChemotherapyGlioblastoma Drug TherapyGlioblastoma PrognosisGlioma ChemotherapyHematologic Toxicity AssessmentLomustine TherapyProcarbazine Therapy
The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.
11
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Philippe Rougier, Antoine Adenis, Michel Ducreux et al. · European Journal of Cancer · 2000 · 752 citations
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Marie‐Claire Y. de Wit, Hein G. de Bruin, W M H Eijkenboom et al. · Neurology · 2004 · 355 citations